Zobrazeno 1 - 10
of 305
pro vyhledávání: ''
Autor:
Biemans, V.B.C., Woude, C.J. van der, Dijkstra, G., Meulen-de Jong, A.E. van der, Lowenberg, M., Boer, N.K. de, Oldenburg, B., Srivastava, N., Jansen, J.M., Bodelier, A.G.L., West, R.L., Vries, A.C. de, Haans, J.J.L., Jong, D. de, Hoentjen, F., Pierik, M.J., Dutch Initiative Crohn Colitis ICC
Publikováno v:
Alimentary Pharmacology & Therapeutics, 52(1), 123-134. Wiley
Biemans, V B C, van der Woude, C J, Dijkstra, G, van der Meulen-de Jong, A E, Löwenberg, M, de Boer, N K, Oldenburg, B, Srivastava, N, Jansen, J M, Bodelier, A G L, West, R L, de Vries, A C, Haans, J J L, de Jong, D, Hoentjen, F & Pierik, M J 2020, ' Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment ', Alimentary Pharmacology and Therapeutics, vol. 52, no. 1, pp. 123-134 . https://doi.org/10.1111/apt.15745
Alimentary Pharmacology & Therapeutics, 52, 1, pp. 123-134
Alimentary pharmacology & therapeutics, 52(1), 123-134. Wiley-Blackwell
Alimentary Pharmacology & Therapeutics
Alimentary Pharmacology & Therapeutics, 52(1), 123-134. Wiley-Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics, 52, 123-134
Alimentary Pharmacology and Therapeutics, 52(1), 123-134. WILEY
Alimentary Pharmacology and Therapeutics, 52(1), 123-134
Biemans, V B C, van der Woude, C J, Dijkstra, G, van der Meulen-de Jong, A E, Löwenberg, M, de Boer, N K, Oldenburg, B, Srivastava, N, Jansen, J M, Bodelier, A G L, West, R L, de Vries, A C, Haans, J J L, de Jong, D, Hoentjen, F & Pierik, M J 2020, ' Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment ', Alimentary Pharmacology and Therapeutics, vol. 52, no. 1, pp. 123-134 . https://doi.org/10.1111/apt.15745
Alimentary Pharmacology & Therapeutics, 52, 1, pp. 123-134
Alimentary pharmacology & therapeutics, 52(1), 123-134. Wiley-Blackwell
Alimentary Pharmacology & Therapeutics
Alimentary Pharmacology & Therapeutics, 52(1), 123-134. Wiley-Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics, 52, 123-134
Alimentary Pharmacology and Therapeutics, 52(1), 123-134. WILEY
Alimentary Pharmacology and Therapeutics, 52(1), 123-134
Contains fulltext : 220027.pdf (Publisher’s version ) (Open Access) BACKGROUND: Both vedolizumab and ustekinumab can be considered for the treatment of Crohn's disease (CD) when anti-TNF treatment fails. However, head-to-head trials are currently n
Publikováno v:
Aliment Pharmacol Ther
BACKGROUND Hepatic encephalopathy is a devastating complication of cirrhosis. AIM To describe the outcomes after developing hepatic encephalopathy among contemporary, aging patients. METHODS We examined data for a 20% random sample of United States M
Autor:
Neena S. Abraham, Jeph Herrin, Lindsey R. Sangaralingham, Nilay Shah, Jonathan Inselman, Che Ngufor, Eric H. Yang, Xiaoxi Yao, Peter A. Noseworthy
Publikováno v:
Aliment Pharmacol Ther
SUMMARY: BACKGROUND: Gastrointestinal bleeding (GIB) frequently occurs following percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) with the prescription of P2Y(12) inhibiting antiplatelet agents. Compared with clopidogrel, th
Publikováno v:
Alimentary pharmacologytherapeutics. 51(1)
Background: Vedolizumab is a gut‐selective antibody to α4β7 integrin approved to treat moderate‐to‐severe Crohn's disease and ulcerative colitis in adults. Inflammatory bowel disease (IBD) and immunosuppressant use are associated with increas
Autor:
Anil Nayyar, Jenna L. Koliani-Pace, Kerry Jo Lee, Eric D. Shah, Corey A. Siegel, Elliot Coburn
Publikováno v:
Aliment Pharmacol Ther
Background Hepatosplenic T-cell lymphoma (HSTCL) is a rare, poorly treatable malignancy associated with therapy for IBD. Current knowledge of HSTCL risk in IBD comes from an era of step-up therapy, before earlier use of biologics or combination thera
Autor:
Peter J. Whorwell, Gulzar Singh, Beate Niesler, Verena Wahl, Melanie Lingaya, Robin C. Spiller, David Gunn, Ian P. Hall, Klara Garsed, Amanda P. Henry, Ching Lam
Publikováno v:
Alimentary Pharmacology & Therapeutics
Gunn, D, Garsed, K, Lam, C, Singh, G, Lingaya, M, Wahl, V, Niesler, B, Henry, A, Hall, I P, Whorwell, P & Spiller, R 2019, ' Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron ', Alimentary Pharmacology & Therapeutics, vol. 50, no. 5, pp. 538-546 . https://doi.org/10.1111/apt.15420
Gunn, D, Garsed, K, Lam, C, Singh, G, Lingaya, M, Wahl, V, Niesler, B, Henry, A, Hall, I P, Whorwell, P & Spiller, R 2019, ' Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron ', Alimentary Pharmacology & Therapeutics, vol. 50, no. 5, pp. 538-546 . https://doi.org/10.1111/apt.15420
BACKGROUND: Irritable bowel syndrome with diarrhoea (IBS-D) is a common condition, greatly reducing the quality of life with few effective treatment options available.AIM: To report the beneficial response shown in our trial with the 5-hydroyxtryptam
Autor:
Peter C. Hayes, Nikhil Vergis, Michael Allison, Rohit A. Sinha, Ashwin Dhanda, Sumita Verma, Stephen D. Ryder, Dev Katarey, Anne McCune, Mark Thursz, Paul G. Richardson, Andrew Fraser, Jonathan R Potts, Richard D. Parker, Andrew Austin, Ewan Forrest, Steven Masson, Natasha Storey, Stephen R. Atkinson
Publikováno v:
Forrest, E H, Storey, N, Sinha, R, Atkinson, S R, Vergis, N, Richardson, P, Masson, S, Ryder, S, Thursz, M R, Allison, M, Fraser, A, Austin, A, McCune, A, Dhanda, A, Katarey, D, Potts, J, Verma, S, Parker, R & Hayes, P 2019, ' Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. ', Alimentary Pharmacology and Therapeutics, vol. 50, no. 4 . https://doi.org/10.1111/apt.15335
Background\ud Treating severe alcoholic hepatitis involves the exposure of patients to corticosteroids for 7 days to assess “response”.\ud \ud Aim\ud To assess the prognostic and therapeutic implications of baseline neutrophil‐to‐lymphocyte r
Autor:
Romil Saxena, Archita P. Desai, Oscar W. Cummings, Raj Vuppalanchi, Eduardo Vilar-Gomez, Naga Chalasani, Marwan Ghabril, Samer Gawrieh
Publikováno v:
Alimentary pharmacologytherapeutics. 50(3)
Background Metformin may protect against hepatocellular carcinoma and mortality among patients with type 2 diabetes. Aim To investigate whether long-term use of metformin improves survival and reduces liver-related outcomes among patients with type 2
Autor:
J Schultheiss, Eelco C. Brand, Willemijn C.M. van den Berg, Fiona D.M. van Schaik, Evert Lamers, Bas Oldenburg, Herma H. Fidder
Publikováno v:
Alimentary Pharmacology & Therapeutics, 50(4), 386. Wiley-Blackwell
Background In rheumatoid arthritis and psoriasis female sex has been shown to be associated with discontinuation of anti-tumour necrosis factor-α (TNF-α) therapy. Aim To retrospectively assess the association between sex and TNF-α drug persistence
Autor:
Nanne K. H. de Boer, Hans J C Buiter, Adriaan A. van Bodegraven, Melek Simsek, Dennis R Wong, Chris J. J. Mulder, Margien L. Seinen, Matthijs van Luin, Birgit I. Lissenberg-Witte, Carmen S. Horjus, Melanie V. Bénard, Debbie S. Deben
Publikováno v:
Alimentary Pharmacology & Therapeutics
Alimentary Pharmacology and Therapeutics, 50(1), 54-65
Simsek, M, Deben, D S, Horjus, C S, Bénard, M V, Lissenberg-Witte, B I, Buiter, H J C, van Luin, M, Seinen, M L, Mulder, C J J, Wong, D R, de Boer, N K H & van Bodegraven, A A 2019, ' Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies ', Alimentary Pharmacology and Therapeutics, vol. 50, no. 1, pp. 54-65 . https://doi.org/10.1111/apt.15280
Alimentary Pharmacology and Therapeutics, 50(1), 54-65
Simsek, M, Deben, D S, Horjus, C S, Bénard, M V, Lissenberg-Witte, B I, Buiter, H J C, van Luin, M, Seinen, M L, Mulder, C J J, Wong, D R, de Boer, N K H & van Bodegraven, A A 2019, ' Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies ', Alimentary Pharmacology and Therapeutics, vol. 50, no. 1, pp. 54-65 . https://doi.org/10.1111/apt.15280
Background: Tioguanine (or thioguanine) is an alternative drug for IBD patients who fail prior conventional immunomodulating therapy. Aim: To report effectiveness, safety and therapeutic drug monitoring in a cohort of patients with prolonged tioguani